1541 — ImmuneOnco Biopharmaceuticals Shanghai Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$3.33bn
- HK$3.40bn
- CNY0.39m
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | — |
Source: | PROSPECTUS | PROSPECTUS | |
Standards: | IFRS | IFRS | — |
Status: | Final | Final | fx Preliminary |
Net Income/Starting Line | -733 | -403 | — |
Depreciation | |||
Non-Cash Items | 555 | 134 | — |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | -25.7 | 12.5 | — |
Change in Accounts Receivable | |||
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Other Operating Cash Flow | |||
Cash from Operating Activities | -191 | -239 | — |
Capital Expenditures | -125 | -23.2 | — |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | 16.5 | 23.3 | — |
Sale of Fixed Assets | |||
Sale/Maturity of Investment | |||
Purchase of Investments | |||
Other Investing Cash Flow | |||
Cash from Investing Activities | -109 | 0.049 | — |
Financing Cash Flow Items | -3.17 | -4.39 | — |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 793 | 179 | — |
Foreign Exchange Effects | |||
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 485 | -33.1 | — |